This Week’s Top Gainers Review
I. Headline Narrative: “Revalidation” of mRNA Vaccines Ignites a Biotech Revaluation Rally The biggest narrative in global markets this week was that the Phase III clinical trial of the mRNA melanoma vaccine jointly developed by Moderna and Merck reached its primary endpoint. When combined with Keytruda, the vaccine significantly reduced the risks of recurrence and metastasis. This marks the second major validation of the mRNA technology platform after COVID-19 vaccines, and its significance ext
GateLighthouse·08-21 01:15


